• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

    27.69 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,304
    Open 27.69
    Bid (Size) 27.56 (100)
    Ask (Size) 28.00 (1,000)
    Prev. Close 27.69
    Today's Range 27.69 - 27.69
    52wk Range 12.59 - 47.65
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision ↗
    This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
    Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    -22.5%
    -22.5%
    1 Month
    +16.9%
    +16.9%
    3 Month
    -1.9%
    -1.9%
    6 Month
    -22.3%
    -22.3%
    1 Year
    +104.7%
    +104.7%

    More News

    Read More
    News headline image
    Mineralys (MLYS) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Mineralys Therapeutics Inc (NASDAQ:MLYS) First Quarter 2026 Results Show Modest Market Reaction to FDA NDA Acceptance ↗
    Via Chartmill
    Mineralys Therapeutics Inc (NASDAQ:MLYS) Reports Q4 2025 EPS Beat and Key FDA NDA Acceptance for Lorundrostat ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 10, 2025 ↗
    Via Benzinga
    News headline image
    Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Mineralys (MLYS) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate ↗
    Via Chartmill
    News headline image
    Uncovering Potential: Mineralys Therapeutics's Earnings Preview ↗
    Via Benzinga
    News headline image
    These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗
    Via The Motley Fool
    News headline image
    It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗
    Via The Motley Fool
    Topics Economy Stocks
    News headline image
    These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗
    Via The Motley Fool
    News headline image
    Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
    Via Benzinga
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Nasdaq Down 1%; Signet Jewelers Earnings Top Views ↗
    Via Benzinga

    Frequently Asked Questions

    Is Mineralys Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Mineralys Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Mineralys Therapeutics, Inc. - Common Stock trade on?
    Mineralys Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Mineralys Therapeutics, Inc. - Common Stock?
    The ticker symbol for Mineralys Therapeutics, Inc. - Common Stock is MLYS on the Nasdaq Stock Market
    What is the current price of Mineralys Therapeutics, Inc. - Common Stock?
    The current price of Mineralys Therapeutics, Inc. - Common Stock is 27.69
    When was Mineralys Therapeutics, Inc. - Common Stock last traded?
    The last trade of Mineralys Therapeutics, Inc. - Common Stock was at 07/02/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.